CSP Inc stock faces scrutiny amid AI hardware demand slowdown and earnings anticipation

CSP INC /MA/ (CSPI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CSPi Reports FY2026 Third Quarter Results AZT PROTECT Performance and High Customer Satisfaction Generates 100% Renewal Rate; TS Order Backlog Continues Year-Over-Year Growth; Recent Surge of Large Cloud-based Services Contracts Combine with AZT PROTECT & TS Opportun

CSP Inc. (NASDAQ: CSPI) reported fiscal Q3 ended June 30, 2026 sales of $14.4 million versus $15.4 million a year earlier. Gross margin rose to 30.1% from 28.8%. Net loss was $846,000, or $0.09 per share. Cash was $24.7 million. Board declared a $0.03 quarterly dividend.

Lockheed Martin awarded L3Harris Technologies a $4.7b contract over seven years for PAC-3 MSE rocket motors. The deal supports L3Harris' propulsion segment and ties into new manufacturing facilities in Camden, Arkansas, expected to open in 2027. Analysts project $28.0b revenue and $3.0b earnings by 2029, with a 38% potential upside. Risks include margin management, debt, and U.S. budget decisions.

Combined BHP Ports Unions will seek arbitration with BHP over a wage deal dispute for Port Hedland iron ore operations. The union, representing 450 workers, seeks a four-year agreement, while BHP offered a 17% pay increase and A$25,000 transition payment. The union claims 40% of workers would be worse off under BHP's proposal.

Sempra Infrastructure signed a 20-year LNG supply deal with Petrobras for 800,000 tonnes per year, sourced from its Port Arthur LNG Phase 2 project in Texas. The agreement adds Petrobras as Sempra's first South American LNG customer. Port Arthur Phase 2, with a $14 billion estimated cost, is set to add 13 million tonnes per annum of liquefaction capacity and begin operations in 2030-2031. Sempra has previously secured LNG agreements with ConocoPhillips, JERA, and EQT for Phase 2.

Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed in Phase 3 trials, testing different cardiovascular risk theories. Both drugs did not reduce cardiovascular events despite lowering targets. Novartis reported pelacarsen's Lp(a)HORIZON trial results, while Novo Nordisk halted ziltivekimab's HERMES and ATHENA trials. Analysts estimated pelacarsen's peak sales at $4B-$6B. Both companies have other trials ongoing.